SITC 2022 - mIF Poster
October 25, 2022
Never Miss an Update
Sign up and receive Discovery updates, blogs, and market news directly to your inbox.Subscribe Now
A promising approach for cancer immunophenotyping, in the context of clinical trials, is the usage of in situ multiplexed immuno-fluorescence (mIF) assays. We demonstrate Discovery’s highly standardized approach to novel mIF assay implementation (Fig.1), focusing on the key steps in the wet lab procedure. Detailed phenotyping of spatial distribution patterns within the tumor microenvironment e.g., localization of lymphocytes, myeloid cells, fibroblasts and blood/lymphatic vessels, is an increasingly important tool for the identification of novel prognostic and predictive biomarkers for personalized cancer therapy.
To propel your projects with The Power of Discovery.™
Contact Us Today
Let us know about your project!